NewPace
NewPace Ltd. is an Israel-based medical device company developing the DBelt™ wearable cardioverter-defibrillator and the ISSD™ implantable subcutaneous string defibrillator, plus a Connected Care cloud monitoring platform, to provide short- and long-term protection for patients at risk of sudden cardiac arrest.
- Company typePrivate
- Founded2015
- HeadquartersCaesarea, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NewPace does
NewPace Ltd. is an Israel-based, privately held medical device company founded in 2015 and headquartered in Caesarea, developing a platform of wearable and implantable cardioverter-defibrillator devices for the monitoring and protection of patients at risk of sudden cardiac arrest (SCA). The company employs 11-50 people and is backed by BioStar Ventures, SCP Vitalife, Haisco Pharmaceutical, and a group of US physician-investors, with a Scientific Advisory Board that includes senior electrophysiologists from Mount Sinai, Massachusetts General Hospital, University of Michigan, and Texas Cardiac Arrhythmia Institute, as well as Marius Nacht, founder of Check Point Software Technologies.
The technology portfolio centers on two pre-commercial devices. DBelt™ is a belt-shaped wearable cardioverter-defibrillator with disposable weekly patches, wireless recharging every two weeks, and smartphone/cloud connectivity, intended for short-term SCA protection in post-myocardial infarction patients with borderline left ventricular ejection fraction during the transition period before ICD decision or implantation. ISSD™ is a novel rechargeable implantable subcutaneous string defibrillator with a unitary flexible string-like shape, implanted via three small incisions with no fluoroscopy, no leads within the heart, and no pulse generator pocket, intended for long-term SCA protection. A Connected Care cloud platform provides continuous remote patient monitoring for both devices and is positioned to support future AI-based analytics. The ISSD completed a first-in-man feasibility trial reported at Heart Rhythm 2017; neither product is yet approved for commercial use.
The business model is pre-revenue. Once regulatory clearance is achieved, NewPace expects to generate revenue from hardware sales of the wearable DBelt and implantable ISSD devices through enterprise field sales targeting hospitals and cardiac electrophysiology departments, with potential recurring revenue from the Connected Care monitoring platform. GTM relies on physician key-opinion-leader engagement and presence at major cardiology conferences such as Heart Rhythm Society. The company received EU Horizon 2020 SME Instrument grant funding in 2018 in addition to a 2017 private round from founders and US physicians; specific funding amounts have not been disclosed.
NewPace firmographics
Firmographics- Name
- NewPace
- Legal name
- NewPace Ltd.
- Website
- https://newpacemedical.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NewPace Ltd. is an Israel-based medical device company developing the DBelt™ wearable cardioverter-defibrillator and the ISSD™ implantable subcutaneous string defibrillator, plus a Connected Care cloud monitoring platform, to provide short- and long-term protection for patients at risk of sudden cardiac arrest.
- Ownership category
- akta.pro rank
NewPace industry classification
Industry- Product category
- Cardiac Rhythm Management Medical Devices
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Rhythm Management (Pacemakers, ICDs, CRT) (HLAHAFAC)
- akta.pro secondary industries
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB), Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG)
Keywords
Where NewPace is headquartered
LocationHeadquarters
- HQ city
- Caesarea
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
NewPace business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: Both DBelt and ISSD are development stage products not yet approved for commercial use. Once commercially launched, the company will generate revenue from sale of medical devices. DBelt is a wearable device; ISSD is an implantable device.
- Remote Monitoring Services: Connected Care platform provides cloud-based patient monitoring capabilities via patient app and cloud connectivity. Future revenue potential from subscription-based remote monitoring services associated with device usage.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
NewPace product offering
Product offeringCore offering
NewPace develops a platform of innovative medical devices for monitoring and protecting patients at risk of sudden cardiac arrest (SCA). Its portfolio includes the DBelt, a belt-shaped wearable cardioverter defibrillator for short-term protection, and the ISSD, a first-of-its-kind rechargeable subcutaneous string-shaped implantable cardioverter defibrillator for long-term protection, complemented by a cloud-based Connected Care remote patient monitoring platform.
Product overview
NewPace is developing a platform of innovative wearable and implantable medical devices for cardiac rhythm management. The portfolio consists of three products: DBelt™ (a wearable cardioverter defibrillator for short-term patient protection), ISSD™ (an implantable subcutaneous string defibrillator for long-term protection), and Connected Care (a cloud-based remote monitoring platform that links both devices). Both the DBelt™ and ISSD™ are development-stage products that provide patient monitoring capabilities and defibrillation protection for patients at risk of sudden cardiac arrest.
Differentiator
Problem solved
Functional benefit
Brands
- DBelt: Wearable Cardioverter Defibrillator (WCD) for short-term SCA protection, intended for post-MI patients with borderline LVEF in transition period prior to ICD implantation.
- ISSD
- Connected Care
Products and services
- DBelt™ A belt-shaped wearable cardioverter defibrillator (WCD) designed for post-myocardial infarction patients with borderline left ventricular ejection fraction (LVEF) during the transition period prior to ICD implantation, or for patients who may not require permanent ICD. Features lightweight belt form factor, minimal skin contact patches replaced weekly, wireless recharging every two weeks, smartphone connectivity via patient app, and remote monitoring capabilities.
- ISSD™ The Implantable Subcutaneous String Defibrillator (ISSD) is a novel rechargeable implantable cardioverter defibrillator (ICD) with a unitary, flexible, low-profile string-like shape. It is the first rechargeable ICD with secure BLE communication. Implantation requires only 3 small incisions, with no leads placed within the heart, no pulse generator pocket, no fluoroscopy required, and can potentially be performed as an outpatient procedure.
- Connected Care A cloud-based remote patient monitoring platform that provides connectivity for both the DBelt and ISSD devices. Enables online continuous patient monitoring, big data collection, personalized care, location-based emergency services support, and future AI-based analysis capabilities.
Quantifiable outcome
- First-in-man clinical trial demonstrated feasibility and effectiveness of string-shaped implantable defibrillator in treating patients with irregular heartbeats (May 2017)
Companies that use NewPace
Customer profileSegments2 records
Ideal customer profiles1 record
NewPace technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
NewPace partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights5 records
NewPace competitors and assessment
Company assessmentEmerging players
- Element Science: Developer of a wearable defibrillator patch with cloud connectivity and machine-learning-driven detection. Directly comparable to NewPace's DBelt on the wearable-plus-connected-care combination.
- iRhythm Technologies: Connected cardiac monitoring company (Zio patch) focused on arrhythmia detection rather than defibrillation. Comparable on the Connected Care / cloud-monitoring + wearable device combination but does not deliver therapy.
- Imricor Medical Systems: Cardiac electrophysiology innovator building MRI-guided ablation catheters. Comparable as a small-cap, development-stage cardiac device company pursuing a novel EP architecture, though its therapeutic focus is ablation rather than defibrillation.
- Kestra Medical Technologies: Emerging wearable defibrillator competitor pursuing a more patient-friendly WCD design with sensor-based arrhythmia detection. Represents a newer entrant taking the same displacement angle against ZOLL LifeVest that DBelt targets.
Broad incumbents
- Biotronik: European ICD/CRM manufacturer offering transvenous and home-monitoring-enabled devices. Competes with ISSD in the implantable category and has strong EU hospital relationships relevant to NewPace's Horizon 2020-backed launch.
- Medtronic: Global ICD market leader with the longest-running transvenous and newer leadless/smart ICD platforms. Competes against both NewPace products through established physician relationships and deep clinical evidence base.
- MicroPort Scientific: Cardiac rhythm management division offers ICD and CRT-D devices competing with ISSD, with growing presence in Europe and Asia where NewPace may initially launch.
- Boston Scientific: Dominant player in the subcutaneous ICD market via the EMBLEM S-ICD system — the most direct competitor to NewPace's ISSD. Also operates broadly in cardiac rhythm management, EP ablation, and structural heart, giving it scale, sales force, and clinical-trial infrastructure NewPace lacks.
- Abbott: Major ICD/CRM player with the Gallant ICD family and Aveir leadless pacemaker platform. Active in adjacent innovation (leadless, communication-enabled devices) and a credible next-gen competitor to ISSD.
Direct peers
- ZOLL Medical (Asahi Kasei): Owner of the LifeVest wearable cardioverter defibrillator — the established standard of care that NewPace's DBelt directly targets for short-term post-MI SCA protection. Most direct competitor to the DBelt product line.
Market position
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
NewPace social profiles
Digital presenceNewPace financial estimates
Financial estimateRevenue estimate
Valuation estimate
NewPace leadership team
Management profileNumber of profiles
Profiles13 records
NewPace funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NewPace M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NewPace
What does NewPace do?
NewPace develops a platform of innovative medical devices for monitoring and protecting patients at risk of sudden cardiac arrest (SCA). Its portfolio includes the DBelt, a belt-shaped wearable cardioverter defibrillator for short-term protection, and the ISSD, a first-of-its-kind rechargeable subcutaneous string-shaped implantable cardioverter defibrillator for long-term protection, complemented by a cloud-based Connected Care remote patient monitoring platform.
Is NewPace a public or private company?
NewPace is a private company. It is classified as venture growth investor backed and is currently operating.
When was NewPace founded?
NewPace was founded in 2015. It employs 11 to 50 people.
Where is NewPace based?
NewPace is headquartered in Caesarea, Israel, in the Middle East region.
How does NewPace make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are remote Monitoring Services.
Who are NewPace's main competitors?
Emerging players on record are Element Science, iRhythm Technologies, Imricor Medical Systems and Kestra Medical Technologies. Broad incumbents are Biotronik, Medtronic, MicroPort Scientific, Boston Scientific and Abbott. ZOLL Medical (Asahi Kasei) is listed as a direct peer.
Does NewPace have an API?
No public API is recorded for NewPace.
What industry is NewPace in?
NewPace's product category is Cardiac Rhythm Management Medical Devices. Its primary akta.pro industry code is HLAHAFAC, Cardiac Rhythm Management (Pacemakers, ICDs, CRT), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its SIC code is 3841.